olaparib,abiraterone
astrazeneca,merck
['crpc', 'abira', 'olaparib', 'propel', 'prostate', 'abiraterone']
#ascogu23 final overall survival (os) in propel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1l) therapy for metastatic castration-resistant prostate cancer (mcrpc). 
Medicina Interna - Oncología Clínica - Clínica Astorga. Profesor titular @upbcolombia #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis